期刊
PHARMACOGENETICS AND GENOMICS
卷 16, 期 12, 页码 911-914出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.fpc.0000230421.12844.fd
关键词
C-reactive protein; Crohn's disease; IgG Fc receptor; infliximab; polymorphism; tumor necrosis factor
Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn's disease. We further assessed this association in a subset of 344 patients from the large and well-defined cohort of 573 patients with Crohn's disease from the ACCENT I study. No association could be observed between FCGR3A-158 gene polymorphism and the clinical response to infliximab, which was primarily defined as a decrease of 2-70 points in the Crohn's disease activity index or clinical remission (Crohn's disease activity index < 150). We did, however, confirm a trend towards a greater decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F homozygotes (-79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P=0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据